EUVIMEDEUVIMED entdecken
Open Access

Epigenome Editing Durability Varies Widely Across Cardiovascular Disease Target Genes

Madelynn N Whittaker iD, Lauren C Testa, Aidan Quigley, Ishaan Jindal, Saúl V Cortez-Alvarado, Ping Qu, Yifan Yang, Mohamad-Gabriel Alameh iD, Kiran Musunuru iD, Xiao Wang iD

Arteriosclerosis, Thrombosis, and Vascular Biology · 2023-10 · 43 (10) · 2075-2077

DOI: 10.1161/atvbaha.123.319748 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2023-10. Verfasst von Madelynn N Whittaker und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine and Cardiovascular Institute (M.N.W., L.C.T., A.Q., I.J., S.V.C.-A., P.Q., Y.Y., K.M., X.W.), Perelman School of …. Hauptthemen laut MEDLINE: Epigenome, Cardiovascular Diseases. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hepatic knockdown of the proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) gene or the angiopoietin-like 3 ( ANGPTL3 ) gene has been demonstrated to reduce blood low-density lipoprotein cholesterol (LDL-C) levels, and hepatic knockdown of the angiotensinogen ( AGT ) gene has been demonstrated to reduce blood pressure. Genome editing can productively target each of these three genes in hepatocytes in the liver, offering the possibility of durable “one-and-done” therapies for hypercholesterolemia and hypertension. However, concerns around making permanent gene sequence changes via DNA strand breaks might hinder acceptance of these therapies. Epigenome editing offers an alternative approach to gene inactivation, via silencing of gene expression by methylation of the promoter region, but the long-term durability of epigenome editing remains to be established.

Methods

We assessed the ability of epigenome editing to durably reduce the expression of the human PCSK9, ANGPTL3 , and AGT genes in HuH-7 hepatoma cells. Using the CRISPRoff epigenome editor, we identified guide RNAs that produced efficient gene knockdown immediately after transfection. We assessed the durability of gene expression and methylation changes through serial cell passages.

Results

Cells treated with CRISPRoff and PCSK9 guide RNAs were maintained for up to 124 cell doublings and demonstrated durable knockdown of gene expression and increased CpG dinucleotide methylation in the promoter, exon 1, and intron 1 regions. In contrast, cells treated with CRISPRoff and ANGPTL3 guide RNAs experienced only transient knockdown of gene expression. Cells treated with CRISPRoff and AGT guide RNAs also experienced transient knockdown of gene expression; although initially there was increased CpG methylation throughout the early part of the gene, this methylation was geographically heterogeneous—transient in the promoter, and stable in intron 1.

Conclusions

This work demonstrates precise and durable gene regulation via methylation, supporting a new therapeutic approach for protection against cardiovascular disease via knockdown of genes such as PCSK9 . However, the durability of knockdown with methylation changes is not generalizable across target genes, likely limiting the therapeutic potential of epigenome editing compared to other modalities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EpigenomeCardiovascular DiseasesHumansEpigenesis, GeneticCRISPR-Cas SystemsGene EditingDNA Methylation

Stichwörter der Autor:innen

cardiovascular diseasescholesterolepigenomegene editinglipoprotein

Autor:innen und Institutionen

  • Division of Cardiovascular Medicine and Cardiovascular Institute (M.N.W., L.C.T., A.Q., I.J., S.V.C.-A., P.Q., Y.Y., K.M., X.W.), Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
  • Department of Bioengineering, University of Pennsylvania, Philadelphia (M.N.W.).
  • Division of Infectious Diseases (M.-G.A.), Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.

ORCID-Profile: Madelynn N Whittaker, Mohamad-Gabriel Alameh, Kiran Musunuru, Xiao Wang

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Whittaker, M. N., Testa, L. C., Quigley, A., Jindal, I., Cortez-Alvarado, S. V., Qu, P., Yang, Y., Alameh, M. G., Musunuru, K., & Wang, X. (2023). Epigenome Editing Durability Varies Widely Across Cardiovascular Disease Target Genes. Arteriosclerosis, Thrombosis, and Vascular Biology, 43(10), 2075-2077. https://doi.org/10.1161/atvbaha.123.319748

Vancouver

Whittaker MN, Testa LC, Quigley A, Jindal I, Cortez-Alvarado SV, Qu P, et al. Epigenome Editing Durability Varies Widely Across Cardiovascular Disease Target Genes. Arteriosclerosis, Thrombosis, and Vascular Biology. 2023;43(10):2075-2077. doi:10.1161/atvbaha.123.319748

BibTeX
@article{Whittaker2023,
  author = {Whittaker, Madelynn N and Testa, Lauren C and Quigley, Aidan and Jindal, Ishaan and Cortez-Alvarado, Saúl V and Qu, Ping and Yang, Yifan and Alameh, Mohamad-Gabriel and Musunuru, Kiran and Wang, Xiao},
  title = {Epigenome Editing Durability Varies Widely Across Cardiovascular Disease Target Genes},
  journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
  year = {2023},
  volume = {43},
  number = {10},
  pages = {2075--2077},
  doi = {10.1161/atvbaha.123.319748}
}
Kostenlos starten →